Australian and New Zealand Urogenital and Prostate Cancer Trials Group
21
3
10
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
4.8%
1 terminated/withdrawn out of 21 trials
85.7%
-0.8% vs industry average
33%
7 trials in Phase 3/4
33%
2 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Role: collaborator
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Role: collaborator
Working Out M0 Bipolar Androgen Therapy
Role: lead
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
Role: lead
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
Role: collaborator
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Role: collaborator
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
Role: collaborator
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Role: lead
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
Role: collaborator
Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer
Role: lead
BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer
Role: collaborator
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
Role: lead
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
Role: lead
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
Role: collaborator
Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer
Role: collaborator
Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma
Role: lead
Radiotherapy - Adjuvant Versus Early Salvage
Role: collaborator
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
Role: lead
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
Role: lead
Evaluation of a Patient-Reported Symptom Index for NMIBC
Role: collaborator